European Patent Office Upholds Angiotech's Patent For Drug-Coated Stents
The EPO maintained the validity of Angiotech's patent with various claims, including claims to stents coated with paclitaxel and a polymeric carrier.
“This decision reaffirms Angiotech's continued patent protection in Europe,” the company said in a statement.
The patent is one of many in Angiotech's portfolio, including the Boston Scientific Taxus stent program. The stents, coated with paclitaxel and a polymeric...
To view the full article, register now.